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Abstract
Background: Recent biotechnological developments have resulted in increasing interest in immunology
biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response.
Hence, clinical validation of these predictive markers is critical.
Findings: The process of clinically validating a predictive biomarker is reviewed. Validation of a predictive biomarker
requires quantifying the strength of a statistical interaction between marker and a treatment. Different study designs are
considered.
Conclusions: Clinical validation of immunology biomarkers can be demanding both in terms of time and resources, and
careful planning and study design are critical.
Findings
Description of the technology
Appropriate statistical design and data of experiments is
necessary for the successful development of predictive im-
munology biomarkers. Predictive immune response-based
biomarkers may provide “evidence about the probability of
benefit or toxicity” [1] from an immunotherapy approach.
This discussion will focus on biomarkers for benefit. An
ideal predictive marker would allow us to perfectly separate
patients into a group who will respond to the therapy, and
a group who will not respond. The groups are formed
based on biomarker measurements taken either before any
therapy is given, or early on in the treatment regimen.
Predictive markers in the real world do not attain the
ideal sketched in the previous paragraph, and clinical valid-
ation is the process to determine how these imperfect
markers, if actually used in the clinic, will impact clinical
outcomes. In general, this is a complicated question and it
is helpful to break it down into simpler parts. First, the test
needs to be analytically validated. Here, much guidance has
been provided in recent years for assessing and reporting
technical reproducibility [2, 3]. Although immunology
markers present unique technical measurement challenges,
the guidance in these papers may be helpful. Second, the
analytically validated test needs to be clinically validated.
For a predictive biomarker validation study in a phase III
setting, a clinically relevant outcome should be used, one
that reflects “survival or symptomatic status of the subject”
[4], or an approved surrogate outcome that has been
adequately validated. Few such surrogates exist, however.
New end points need to be defined that capture immuno-
therapy related response patterns such as delayed responses,
“progression before regression and delayed survival separ-
ation curves.” Third, an appropriate study design needs to
be put in place and analyzed to validate the predictive
marker. Such a study may be either prospective or use
archived specimens from a clinical trial [5]. How to properly
design and analyze a biomarker validation study is currently
an area of active development, which we will briefly review
next.
A predictive biomarker is clinically useful to the extent
that there is a particular type of statistical interaction be-
tween the biomarker values and the effect of the treatment.
Designing and analyzing studies to assess an interaction is
more difficult than for more standard phase III clinical
studies which test a main effect. But progress has recently
been made [6–12]. For example, Fig. 1 shows the relation-
ship between a hypothetical predictive biomarker’s values
and the probability of 5-year survival, broken down by
treatment groups. From this one can assess the variability
in response to each treatment as a function of marker
value. A similar figure appears in Janes et al. [10]. The opti-
mal biomarker-guided treatment would be that individuals
with marker value below 5 should receive treatment, andCorrespondence: dobbinke@uga.edu
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those with values above 5 should avoid the therapy. Since
the improvement in 5-year survival based on optimal
marker-guided therapy results from assigning those with
marker value below 5 to the treatment, the distance be-
tween the “Control” and “Treatment” curves to the left of 5
characterizes the impact of the marker. Software for esti-
mating this difference is available (TreatmentSelection,
http://labs.fhcrc.org/janes/index.html).
Type of data obtained/readout
This primer has focused on biomarkers that provide a con-
tinuous response since this is likely to be the most frequent
scenario for immune-oncology biomarkers. These types of
biomarkers include univariate “machine readout” settings,
some pathologist scoring settings, multiplex assays and high
dimensional assays (e.g., RNAseq). The latter two are in-
cluded in this category because the multiple dimensions
must be formed into a univariate score in order for clinical
decisions to be made. This is typically done using a linear
combination. In addition, a cutoff point to be used for the
medical treatment decision must be specified. While the
linear combination is typically formed based on statistical
criteria, the selection of the cutoff point should be based
largely on implications for clinical outcomes (e.g., lower tol-
erance for False Negative considering the life threatening
nature of cancer and lack of alternative treatments for ad-
vanced tumors). Other types of biomarkers provide binary
or categorical results.
The readout from software such as TreatmentSelec-
tion is the change in the average probability of 5-year
survival under marker-guided therapy compared to
current standard of care. The “average” here is taken
across the target population.
Limitations of the approach
Biostatistical methods are not yet as well developed for
predictive markers as they are for other types of
markers. Common examples of biomarker study designs
are shown in Fig. 2. The marker strategy design com-
pares a standard of care strategy versus a marker guided
strategy, and is being used in the MINDACT trial [13].
The marker stratified design provides the most complete
information about the biomarker but tends to be the
most expensive. The enrichment design uses the marker
for patient selection.
Types of samples needed and special issues pertaining to
samples
In most cases, clinical validation of a predictive marker
will require samples from a phase III clinical trial in
which individual patients have been randomized to the
therapy to which the marker is predicting response.
Level of evidence
The number of publications discussing the methodologic
aspects of the process of clinical validation of predictive
biomarkers has been growing in parallel with the in-
creasing understanding of the disease biology and the
mechanism of action of cancer drugs, including im-
munotherapy approaches.
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Fig. 1 A predictive biomarker example. The solid line shows the
probability of 5-year survival under treatment; as the biomarker value
increases from 0 to 10, the probability of survival decreases. The
dashed line shows the probability of 5-year survival under a control; as
the biomarker value increases from 0 to 10, the probability of survival
increases. The optimal therapy is: treatment those with biomarker value
below 5, and do not treat those with biomarker value above 5
Fig. 2 Different biomarker designs: Marker strategy design, marker
stratified design, and enrichment design (top to bottom)
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